TEACHING AND EDUCATION SECOND PLACE WINNERS:

Glenn Myers
The Moncton Hospital

Glenn Myers was awarded a 2nd Place HOPE Award in Teaching & Education for his project, ‘Immunotherapy (IO) + VEGFR Tyrosine Kinase Inhibitor (TKI) Patient Education Toolkit’.

Immune checkpoint inhibitors (IOs) and VEGF targeted TKIs (TKIs) are used in combination to treat metastatic renal cell carcinoma (mRCC) and endometrial cancer (mEC). Each medication is associated with unique toxicities correlated to their anti-tumour mechanism, and when these drugs are given in combination, it can be difficult to determine which drug is causing a specific side effect.

Design: The IO + TKI education tool kit was developed to support HCPs in providing effective education to patients receiving this combination treatment. Since patients learn in different ways, the tool kit includes various education tools such as a PDF brochure, video, and a wallet card where they can access these resources in a seamless way. The content of the tool kit focuses on rationale for using IO + TKI treatment, how each are administered, toxicity spectrum of IOs and TKIs, potential overlapping toxicities, and ways they can take an active role in their own care.

Results: The toolkit content was developed between April and October 2023, and education events have introduced this tool across Canada. The IO + TKI patient education toolkit equips pharmacists with the necessary tools to provide robust patient centered education on IO + TKI combination therapy in mRCC and mEC. The content within these resources supports patients to take on a more active role in their care whilst staying informed on the appropriate prophylactic and management strategies for IO + TKI related toxicity.

Overall, the practical and non-industry branded nature of these resources allows pharmacists to seamlessly integrate this into their current practice. These tools can also be an invaluable resource to our colleagues in the community and specialty pharmacy setting who are providing education to patients receiving their oral VEGFR-TKI through their respective pharmacies.

TEACHING AND EDUCATION FIRST PLACE WINNERS:

Laura Minard, Ny Phonchareon, Samantha Scott, Amanda Daniels, Claudia Harding
Nova Scotia Health

Glenn Myers was awarded a 2nd Place HOPE Award in Teaching & Education for his project, ‘Immunotherapy (IO) + VEGFR Tyrosine Kinase Inhibitor (TKI) Patient Education Toolkit’.

Immune checkpoint inhibitors (IOs) and VEGF targeted TKIs (TKIs) are used in combination to treat metastatic renal cell carcinoma (mRCC) and endometrial cancer (mEC). Each medication is associated with unique toxicities correlated to their anti-tumour mechanism, and when these drugs are given in combination, it can be difficult to determine which drug is causing a specific side effect.

Design: The IO + TKI education tool kit was developed to support HCPs in providing effective education to patients receiving this combination treatment. Since patients learn in different ways, the tool kit includes various education tools such as a PDF brochure, video, and a wallet card where they can access these resources in a seamless way. The content of the tool kit focuses on rationale for using IO + TKI treatment, how each are administered, toxicity spectrum of IOs and TKIs, potential overlapping toxicities, and ways they can take an active role in their own care.

Results: The toolkit content was developed between April and October 2023, and education events have introduced this tool across Canada. The IO + TKI patient education toolkit equips pharmacists with the necessary tools to provide robust patient centered education on IO + TKI combination therapy in mRCC and mEC. The content within these resources supports patients to take on a more active role in their care whilst staying informed on the appropriate prophylactic and management strategies for IO + TKI related toxicity.

Overall, the practical and non-industry branded nature of these resources allows pharmacists to seamlessly integrate this into their current practice. These tools can also be an invaluable resource to our colleagues in the community and specialty pharmacy setting who are providing education to patients receiving their oral VEGFR-TKI through their respective pharmacies.